Cerus Corp. CERS

What this company does

Cerus Corporation is a biomedical products company that develops and commercializes the INTERCEPT Blood System. The INTERCEPT Blood System, based on the company's proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The INTERCEPT Blood System is intended for use with platelets, plasma and red blood cells, and to produce INTERCEPT Fibrinogen Complex and pathogen reduced plasma, cryoprecipitate reduced. The company sells the platelet and plasma systems using its direct sales force and through distributors, and sells IFC or disposable kits to manufacture IFC in the U.S. using its direct sales force. As of December 31, 2025, it had 275 employees company-wide. Cerus Corporation was incorporated in California in 1991 and reincorporated in Delaware in 1996.

Written from the business description in CERUS CORP's annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.